Rallybio (NASDAQ:RLYB) Posts Quarterly Earnings Results, Beats Estimates By $8.81 EPS

Posted by Brian Himes on Aug 6th, 2026

Rallybio (NASDAQ:RLYB – Get Free Report) announced its quarterly earnings data on Thursday. The company reported $7.53 earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.28) by $8.81, FiscalAI reports. Rallybio had a negative net margin of 911.07% and a negative return on equity of 55.79%.

Rallybio Stock Up 0.3%

Shares of Rallybio stock traded up $0.05 during midday trading on Thursday, hitting $16.19. The company’s stock had a trading volume of 27,117 shares, compared to its average volume of 43,881. The firm has a market capitalization of $85.81 million, a P/E ratio of -3.73 and a beta of -0.90. The stock has a 50-day simple moving average of $16.01 and a 200-day simple moving average of $11.37. Rallybio has a 1-year low of $3.20 and a 1-year high of $17.57.

Analyst Ratings Changes

Separately, Weiss Ratings restated a “sell (d-)” rating on shares of Rallybio in a report on Friday, May 8th. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the stock has an average rating of “Sell”.

Read Our Latest Stock Analysis on RLYB

Insider Buying and Selling at Rallybio

In other Rallybio news, major shareholder Adar1 Capital Management, Llc purchased 79,259 shares of the company’s stock in a transaction that occurred on Wednesday, May 13th. The shares were purchased at an average cost of $13.99 per share, with a total value of $1,108,833.41. Following the completion of the transaction, the insider owned 909,843 shares of the company’s stock, valued at approximately $12,728,703.57. This represents a 9.54% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this link. Insiders acquired a total of 146,568 shares of company stock worth $2,050,669 in the last quarter. Insiders own 10.30% of the company’s stock.

Institutional Investors Weigh In On Rallybio

A number of institutional investors have recently bought and sold shares of RLYB. XTX Topco Ltd grew its stake in Rallybio by 64.6% during the 4th quarter. XTX Topco Ltd now owns 97,313 shares of the company’s stock valued at $67,000 after acquiring an additional 38,205 shares in the last quarter. Renaissance Technologies LLC lifted its position in shares of Rallybio by 16.9% in the fourth quarter. Renaissance Technologies LLC now owns 835,692 shares of the company’s stock worth $573,000 after purchasing an additional 120,892 shares in the last quarter. Geode Capital Management LLC lifted its position in shares of Rallybio by 1.2% in the fourth quarter. Geode Capital Management LLC now owns 248,005 shares of the company’s stock worth $170,000 after purchasing an additional 2,996 shares in the last quarter. Susquehanna International Group LLP boosted its holdings in shares of Rallybio by 485.9% during the third quarter. Susquehanna International Group LLP now owns 136,294 shares of the company’s stock worth $68,000 after purchasing an additional 113,031 shares during the period. Finally, Citadel Advisors LLC boosted its holdings in shares of Rallybio by 576.1% during the third quarter. Citadel Advisors LLC now owns 438,705 shares of the company’s stock worth $219,000 after purchasing an additional 373,821 shares during the period. 90.34% of the stock is currently owned by institutional investors and hedge funds.

Rallybio Company Profile

(Get Free Report)

Rallybio Therapeutics, Inc (NASDAQ: RLYB) is a clinical‐stage biotechnology company focused on developing and commercializing therapies for people living with rare genetic diseases. The company’s scientific approach leverages diverse modalities—including monoclonal antibodies, small molecules and enzyme replacement—to address high‐unmet‐need conditions in areas such as immunodeficiency, metabolic disorders and dermatologic diseases. Rallybio’s pipeline is designed to advance through registrational clinical trials with the goal of delivering first‐in‐class or best‐in‐class therapies to patients who currently have limited or no approved treatment options.

Among Rallybio’s lead programs is RBX‐100, an investigational therapy for congenital athymia, a rare pediatric immunodeficiency.